In congenital adrenal hyperplasia (CAH), lifelong hormone replacement therapy is required to treat adrenal insufficiency and to reduce elevated androgen levels. This is essential to ensure "normal" growth and puberty. Replacement therapy includes hydrocortisone and 9α-fludrocortisone acetate (as a mineralocorticoid substitute). Defining appropriate criteria for evaluating therapeutic goals is a key component of patient follow-up.
Currently, monitoring is generally limited to the quantification of serum 17-hydroxyprogesterone (17OHP), testosterone (T) and delta-4 androstenedione (D4), measured in the morning after an overnight fast and before the morning hydrocortisone dose. However, such single-point serum measurements do not take into account the circadian rhythm of these steroids.
The objective of the study is to evaluate correlations between steroid levels (21-deoxycortisol, 17-hydroxyprogesterone, testosterone, delta-4 androstenedione, and cortisol) measured by LC-MS/MS in multiple at-home self-collected saliva samples and those measured in serum during routine monitoring.
Inclusion Criteria:
Exclusion Criteria:
muriel.houang@aphp.fr+33 1 44 73 66 31
Children and adolescents with congenital adrenal hyperplasia followed in the participating pediatric endocrinology centers, with 1-2 routine follow-up visits per year, during which paired serum and salivary steroid measurements are obtained.
antonin.lamaziere@aphp.fr+33 1 40 01 14 90
COrticosteroid in Congenital Adrenal Hyperplasia
Salt Wasting, Hydro-sodium Balance and Fludrocortisone Requirement in Congenital Adrenal Hyperplasia
Hydrocortisone Modified-release in Adults: Real-world Monitoring of Longitudinal Outcomes in coNgenital Adrenal hYperplasia
Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia
Dynamic Hormone Diagnostics in Endocrine Disease
Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia
Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia
Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia